product name Alizapride HCl
Description: Alizapride HCl is a dopamine receptor antagonist used for the theropy of nausea and vomiting. Alizapride demonstrates little toxicity (particularly after parenteral administration) in mice and rats. Alizapride is mainly excreted as unmodified drug after oral or parenteral administration; however, a share of about 25% undergoes metabolic transformation before deletion. Alizapride (5 mg/kg, s.c.) antagonizes the decrease in gastrointestinal transit induced by the above doses of Apomorphine in the rat.
References: J Mass Spectrom. 2012 Jun;47(6):737-50; Pharmacol Res. 1993 May-Jun;27(4):335-47.
351.83
Formula
C16H21N5O2.HCl
CAS No.
59338-87-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 42 mg/mL (119.4 mM)
Water: 70 mg/mL (198.95 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19414313
| In Vitro |
In vitro activity: Alizapride has a N-allyl moiety which potentially could undergo N-deallylation and/or epoxidation reactions, the formation of chemically reactive metabolites can be expected. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Alizapride demonstrates little toxicity (particularly after parenteral administration) in mice and rats. Alizapride is mainly excreted as unmodified drug after oral or parenteral administration; however, a share of about 25% undergoes metabolic transformation before deletion. Alizapride (5 mg/kg, s.c.) antagonizes the decrease in gastrointestinal transit induced by the above doses of Apomorphine in the rat. |
| Animal model | |
| Formulation & Dosage | |
| References | J Mass Spectrom. 2012 Jun;47(6):737-50; Pharmacol Res. 1993 May-Jun;27(4):335-47. |
